A Phase 4 interventional study of Glimepiride and Metformin in Type 2 Diabetes Mellitus, sponsored by Sanofi. Completed at 1 site in South Korea. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-01-25.
Sponsored by Sanofi · Phase 4, Interventional, and Treatment
Primary objective:
To find out an optimal regimen of OHA (oral hypoglycaemic agents) in combination with insulin glargine (metformin, glimepiride or metformin+glimepiride) by measuring HbA1c level
Secondary objective:
To compare the incidence of hypoglycemia in each treatment group
9,589 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,332 are open to participants now.
This study's enrollment of 99 is above the median of 81 across 7,713 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Sanofi is the lead sponsor of 1,547 studies on the registry; 88 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 122 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Administration of 4 mg of Glimepiride with Insulin Glargine
Drug: Glimepiride · Drug: Insulin Glargine
Administration of 1500 mg of Metformin with Insulin Glargine
Drug: Metformin · Drug: Insulin Glargine
Administration of a combination of 4mg Glimepiride plus 1000mg Metformin with Insulin Glargine
Drug: Glimepiride · Drug: Metformin · Drug: Insulin Glargine
Once a day before breakfast
After breakfast and supper
Injection in the morning
HbA1c values
Time frame: At baseline to end of treatment
Hypoglycemia events
Time frame: From inclusion to end of study
Percentage of patients with HbA1c < 7%
Time frame: At the end of the study
Fasting Blood Glucose level
Time frame: At the end of the study
This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin